New York — Moderna has become the first vaccine maker to produce a shot targeted at the virus variant discovered in SA, and will ship the doses to the US National Institutes of Health to prepare for a clinical trial.

The Boston-based biotech is taking a three-pronged strategy to address concerns that its vaccine, along with several others, is less effective against the 501. V2 strain. ..

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now